PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Immune checkpoints inhibitors or MAPK inhibitors are currently used as standard of care therapies for patients with advanced melanoma. Here the authors report a phase 1 clinical trial testing the anti-PD-L1 antibody durvalumab in combination with the BRAF inhibitor dafrafenib and the MEK inhibitor t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Antoni Ribas, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael Gordon, Leonel Hernandez-Aya, Donald Lawrence, Jose Lutzky, Wilson H. Miller, Katie M. Campbell, Bruno Delafont, Shannon Marshall, Nancy Mueller, Caroline Robert
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/2021304222154fa1af9d43a174d21c40
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2021304222154fa1af9d43a174d21c40
record_format	dspace
spelling	oai:doaj.org-article:2021304222154fa1af9d43a174d21c402021-12-02T13:57:55ZPD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma10.1038/s41467-020-19810-w2041-1723https://doaj.org/article/2021304222154fa1af9d43a174d21c402020-12-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-19810-whttps://doaj.org/toc/2041-1723Immune checkpoints inhibitors or MAPK inhibitors are currently used as standard of care therapies for patients with advanced melanoma. Here the authors report a phase 1 clinical trial testing the anti-PD-L1 antibody durvalumab in combination with the BRAF inhibitor dafrafenib and the MEK inhibitor trametinib in patients with BRAFV600-mutant melanoma.Antoni RibasAlain AlgaziPaolo A. AsciertoMarcus O. ButlerSunandana ChandraMichael GordonLeonel Hernandez-AyaDonald LawrenceJose LutzkyWilson H. MillerKatie M. CampbellBruno DelafontShannon MarshallNancy MuellerCaroline RobertNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-10 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Antoni Ribas Alain Algazi Paolo A. Ascierto Marcus O. Butler Sunandana Chandra Michael Gordon Leonel Hernandez-Aya Donald Lawrence Jose Lutzky Wilson H. Miller Katie M. Campbell Bruno Delafont Shannon Marshall Nancy Mueller Caroline Robert PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
description	Immune checkpoints inhibitors or MAPK inhibitors are currently used as standard of care therapies for patients with advanced melanoma. Here the authors report a phase 1 clinical trial testing the anti-PD-L1 antibody durvalumab in combination with the BRAF inhibitor dafrafenib and the MEK inhibitor trametinib in patients with BRAFV600-mutant melanoma.
format	article
author	Antoni Ribas Alain Algazi Paolo A. Ascierto Marcus O. Butler Sunandana Chandra Michael Gordon Leonel Hernandez-Aya Donald Lawrence Jose Lutzky Wilson H. Miller Katie M. Campbell Bruno Delafont Shannon Marshall Nancy Mueller Caroline Robert
author_facet	Antoni Ribas Alain Algazi Paolo A. Ascierto Marcus O. Butler Sunandana Chandra Michael Gordon Leonel Hernandez-Aya Donald Lawrence Jose Lutzky Wilson H. Miller Katie M. Campbell Bruno Delafont Shannon Marshall Nancy Mueller Caroline Robert
author_sort	Antoni Ribas
title	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
title_short	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
title_full	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
title_fullStr	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
title_full_unstemmed	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
title_sort	pd-l1 blockade in combination with inhibition of mapk oncogenic signaling in patients with advanced melanoma
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/2021304222154fa1af9d43a174d21c40
work_keys_str_mv	AT antoniribas pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT alainalgazi pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT paoloaascierto pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT marcusobutler pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT sunandanachandra pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT michaelgordon pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT leonelhernandezaya pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT donaldlawrence pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT joselutzky pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT wilsonhmiller pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT katiemcampbell pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT brunodelafont pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT shannonmarshall pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT nancymueller pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma AT carolinerobert pdl1blockadeincombinationwithinhibitionofmapkoncogenicsignalinginpatientswithadvancedmelanoma
_version_	1718392246760374272

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

Ejemplares similares